# DCI Partners

> DCI Partners is a VC fund in Tokyo backing Biotechnology, Health Care and Medical. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 19
- Last investment: Jun 2026
- Lead investor: 26%
- Last fund: Dec 2020
- Last updated: Aug 2026
- Website: https://www.daiwa-inv.co.jp/dcip/

DCI Partners is a venture capital firm specializing in the fields of drug discovery and regenerative medicine.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $21M–$105M |
| Series B | $6.2M–$33M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 63% |
| Health Care | 7 | 37% |
| Medical | 6 | 32% |
| Product Research | 6 | 32% |
| Health Diagnostics | 5 | 26% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 37% |
| Funding Round | 6 | 32% |
| Series A | 3 | 16% |
| Series C | 1 | 5% |
| Venture - Series Unknown | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 14 | 74% |
| Taiwan | 2 | 11% |
| United States | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neusignal Therapeutics | Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses. | $32.8M | Series B | Jun 30, 2026 |  |
| Neusignal Therapeutics | Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses. | $32.8M | Series B | Jun 30, 2026 |  |
| Scohia Pharma | Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic. | $442.5M |  | May 28, 2026 |  |
| Surv Biopharma | Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary drugs and pharmaceutical products. | $14.1M | Series B | Nov 11, 2025 |  |
| Apeximmune Therapeutics | Apeximmune Therapeutics is pioneering a new generation of therapeutic antibodies and biologics that harness the power of the immune system to deliver curative treatments for cancer and autoimmune disease. | $21.3M | Series A | Mar 31, 2025 |  |
| Rege Nephro | Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics. | $15.2M | Series B | Oct 07, 2024 |  |
| Luxna Biotech | Luxana Biotech is a biotechnology firm dedicated to promoting the practical use of safe and effective nucleic acid therapies. Utilizing nucleic acid chemistry technology, the company strives to provide nucleic acid medicines to patients suffering from diseases that currently lack effective treatments. | $1.7M | Series C | Sep 06, 2024 |  |
| AceRNA Technologies | AceRNA contributes to regenerative medicine and drug discovery through the discovery of novel miRNA functions. It began operation in April 2018, with its headquarters in Kyoto in Japan. | $6.2M | Series B | May 07, 2024 |  |
| LUCA Science | LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $29.2M | Series B | Jun 06, 2022 |  |
| K Pharma | K Pharma Is the development Of the Treatment Of the Spinal Cord injury | $12.2M | Venture - Series Unknown | May 24, 2022 |  |

10 of 19 investments shown.

## Co-investors
- [Nippon Venture Capital](https://shizune.co/investors/profile/nippon-venture-capital) — VC Fund, 8 deals together
- [Keio Innovation Initiative](https://shizune.co/investors/profile/keio-innovations-initiative) — VC Fund, 6 deals together
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 6 deals together
- [Fast Track Initiative, Inc.](https://shizune.co/investors/profile/fast-track-initiative) — VC Fund, 4 deals together
- [Nissay Capital](https://shizune.co/investors/profile/nissay-capital) — VC Fund, 4 deals together
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [National Development Fund of Taiwan Government](https://shizune.co/investors/profile/national-development-fund-of-taiwan-government) — VC Fund
- [Darwin Venture Management](https://shizune.co/investors/profile/darwin-venture-management) — VC Fund
- [AVA Angels](https://shizune.co/investors/profile/ava-angels) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)
- [Biotechnology Investors in Taiwan](https://shizune.co/investors/biotechnology-investors-taiwan)
- [Biotech Investors in Taiwan](https://shizune.co/investors/biotech-investors-taiwan)
- [Biotechnology VC Funds in Taiwan](https://shizune.co/investors/biotechnology-vc-funds-taiwan)
- [Biotech VC Funds in Taiwan](https://shizune.co/investors/biotech-vc-funds-taiwan)

## FAQ

### What does DCI Partners invest in?

DCI Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Funding Round stage. Most of the 19 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is DCI Partners's check size?

DCI Partners typically joins rounds of $21M–$105M at Series A and $6.2M–$33M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DCI Partners participates in.

### When did DCI Partners last invest?

The most recent investment recorded for DCI Partners closed in Jun 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co